Neutralizing antibodies against GDF-8 and uses therefor

Details Neutralizing antibodies against GDF-8 and uses therefor Neutralizing antibodies against GDF-8 and uses therefor

2007-07-13

2010-02-02

Kemmerer, Elizabeth C. (Department: 1646)

Chemistry: natural resins or derivatives; peptides or proteins;

Proteins, i.e., more than 100 amino acid residues

Blood proteins or globulins, e.g., proteoglycans, platelet...

C530S387100, C530S387900, C530S388100, C530S387300, C530S388240, C536S023530, C435S069100, C435S320100, C435S325000, C435S252300

Reexamination Certificate

active

07655763

ABSTRACT:
The disclosure provides novel antibodies against growth and differentiation factor-8 (GDF-8), in particular human antibodies, and antibody fragments, including those that inhibit GDF-8 activity in vitro and/or in vivo. The disclosure also provides methods for diagnosing, preventing, or treating degenerative disorders of muscle or bone, or disorders of insulin metabolism.

REFERENCES:
patent: 5639638 (1997-06-01), Wozney et al.
patent: 5700911 (1997-12-01), Wozney et al.
patent: 5723125 (1998-03-01), Chang et al.
patent: 5756457 (1998-05-01), Wang et al.
patent: 5827733 (1998-10-01), Lee et al.
patent: 5914234 (1999-06-01), Lee et al.
patent: 5994618 (1999-11-01), Lee et al.
patent: 6004937 (1999-12-01), Wood et al.
patent: 6096506 (2000-08-01), Lee et al.
patent: 6340668 (2002-01-01), Celeste et al.
patent: 6368597 (2002-04-01), Strassmann et al.
patent: 6369201 (2002-04-01), Barker et al.
patent: 6372454 (2002-04-01), Duan et al.
patent: 6407213 (2002-06-01), Carter et al.
patent: 6437111 (2002-08-01), Wozney et al.
patent: 6465239 (2002-10-01), Lee et al.
patent: 6607884 (2003-08-01), Lee et al.
patent: 6656475 (2003-12-01), Lee et al.
patent: 6696260 (2004-02-01), Lee et al.
patent: 6835544 (2004-12-01), Mathews et al.
patent: 6891082 (2005-05-01), Lee et al.
patent: 7101551 (2006-09-01), Itami et al.
patent: 7192717 (2007-03-01), Hill et al.
patent: 7261893 (2007-08-01), Veldman et al.
patent: 7320789 (2008-01-01), Aghajanian et al.
patent: 7381528 (2008-06-01), Lee et al.
patent: 7393682 (2008-07-01), Lee et al.
patent: 2002/0127234 (2002-09-01), El Halawani et al.
patent: 2002/0150577 (2002-10-01), Lee et al.
patent: 2002/0157125 (2002-10-01), Lee et al.
patent: 2003/0074680 (2003-04-01), Lee et al.
patent: 2003/0104406 (2003-06-01), Wolfman et al.
patent: 2003/0138422 (2003-07-01), Aghajanian et al.
patent: 2003/0162714 (2003-08-01), Hill et al.
patent: 2003/0180306 (2003-09-01), Hill et al.
patent: 2004/0055027 (2004-03-01), Lee et al.
patent: 2004/0077053 (2004-04-01), Lee et al.
patent: 2004/0138118 (2004-07-01), Wolfman et al.
patent: 2004/0181033 (2004-09-01), Han et al.
patent: 2004/0223966 (2004-11-01), Wolfman et al.
patent: 2005/0043232 (2005-02-01), Lee et al.
patent: 2005/0257278 (2005-11-01), Lee et al.
patent: 2006/0240487 (2006-10-01), Nowak et al.
patent: 2006/0240488 (2006-10-01), Nowak et al.
patent: 2008/0178310 (2008-07-01), Lee et al.
patent: 2008/0213426 (2008-09-01), Lee et al.
patent: 1 013 762 (2000-06-01), None
patent: 1 061 940 (2003-12-01), None
patent: 1 444 985 (2004-08-01), None
patent: WO 94-21681 (1994-09-01), None
patent: WO 94-26892 (1994-11-01), None
patent: WO 96-01845 (1996-01-01), None
patent: WO 98/33887 (1998-08-01), None
patent: WO98/35019 (1998-08-01), None
patent: WO 99/02667 (1999-01-01), None
patent: WO 99/06559 (1999-02-01), None
patent: WO 99-24058 (1999-05-01), None
patent: WO 99/24618 (1999-05-01), None
patent: WO 99/40181 (1999-08-01), None
patent: WO 99-45949 (1999-09-01), None
patent: WO 99-56768 (1999-11-01), None
patent: WO 00-11163 (2000-03-01), None
patent: WO 00-43781 (2000-07-01), None
patent: WO 01/05820 (2001-01-01), None
patent: WO 01/58956 (2001-08-01), None
patent: WO 01-64888 (2001-09-01), None
patent: WO 01/90190 (2001-11-01), None
patent: WO 02-09641 (2002-02-01), None
patent: WO 02-068650 (2002-09-01), None
patent: WO 03-027248 (2003-04-01), None
patent: WO 03-037248 (2003-05-01), None
patent: WO 03/072714 (2003-09-01), None
patent: WO 03/072715 (2003-09-01), None
patent: WO 2004/039948 (2004-05-01), None
patent: WO 2004/108157 (2004-12-01), None
patent: WO 2006/102574 (2006-09-01), None
patent: WO 2006/107611 (2006-10-01), None
Queen et al., 1989, PNAS USA 86:10029-10033.
Alexander et al., “Human Parathyroid Hormone 1-34 Reverses Bone Loss In Ovariectomized Mice”,J. Bone Min. Res. 16:1665-1673 (2001).
Alliel et al., “Testican, a Multidomain Testicular Proteoglycan Resembling Modulators of Cell Social Behaviour,”Eur. J. Biochem. 214:347-350 (1993).
Amthor et al., “The Expression and Regulation of Follistatin and a Follistatin-like Gene During Avian Somite Compartmentalization and Myogenesis,”Dev. Biol. 178:343-362 (1996).
Andersson et al., “Repeated In Vivo Determinations of Bone Mineral Density During Parathyroid Hormone Treatment in Ovariectomized Mice”,J. Endocrinol. 170:529-537 (2001).
Ashmore et al., “Comparative Aspects of Muscle Fiber Types in Fetuses of the Normal and ‘Double-Muscled’ Cattle”,Growth38:501-506 (1974).
Attisano et al., “Activation of Signalling by the Activin Receptor Complex,”Mol. Cell. Biol. 16:1066-1073 (1996).
Bakker et al., Duchenne and Becker Muscular Dystrophies. InDiagnostic Criteria for Neuromuscular Disorders, 2nd ed., Emery, ed., Royal Society of Medicine Press, 1998; pp. 1-4.
Bartholin et al., “FLRG, an Activin-Binding Protein, is a New Target of TGFβ Transcription Activation Through Smad Proteins,”Oncogene20:5409-5419 (2001).
Bogdanovich et al., “Functional Improvement of Dystrophic Muscle by Myostatin Blockade”,Nature420:418-421 (2002).
Bork, “Powers and Pitfalls in Sequence Analysis: the 70% Hurdle”Genome Research10:398-400 (2000).
Bork et al., “Go hunting in sequence databases but watch out for the traps”Trends in Genetics12:425-427 (1996).
Brenner, “Errors in genome annotation”Trends in Genetics15:132-133 (1999).
Brown et al., “Physicochemical Activation of Recombinant Latent Transforming Growth Factor-beta's 1,2, and 3”,Growth Factors3:35-43 (1990).
Bulfield et al., “X Chromosome-Linked Muscular Dystrophy (mdx) in the Mouse,”Proc. Natl. Acad. Sci. U.S.A. 81:1189-1192 (1984).
D'Angelo et al., “Authentic Matrix Vesicles Contain Active Metalloproteases (MMP),”J. Biol. Chem. 276:11347-11353 (2001).
Derynck et al., “Human Transforming Growth Factor-β Complementary DNA Sequence and Expression in Normal and Transformed Cells”,Nature316:701-705 (1985).
Doerks et al., “Protein annotation: detective work for function prediction”Trends in Genetics14:248-250 (1998).
Donoghue et al., “Rostrocaudal Gradient of Transgene Expression in Adult Skeletal Muscle,”Proc. Natl. Acad. Sci. U.S.A. 88:5847-5851 (1991).
Emery, “The Muscular Dystrophies,”Lancet359:687-695 (2002).
Escolar et al., “Pharmacologic and Genetic Therapy for Childhood Muscular Dystrophies,”Current Neurology and Neuroscience Reports1:168-174 (2001).
Gamer et al., “Gdf11 is a Negative Regulator of Chondrogenesis and Myogenesis in the Developing Chick Limb,”Dev. Biol. 229:407-420 (2001).
Gamer et al., “A Novel BMP Expressed in Developing Mouse Limb, Spinal Cord, and Tail Bud Is a Potent Mesoderm Inducer inXenopusEmbryos”,Dev. Biol. 208:222-232 (1999).
Gentry et al., “The Pro Domain of Pre-Pro-Transforming Growth Factor β1 When Independently Expressed Is a Functional Binding Protein for the Mature Growth Factor”,Biochemistry29:6851:6857 (1990).
Gillis, “Multivariate Evaluation of the Functional Recovery Obtained by the Overexpression of Utrophin in Skeletal Muscles of themdxMouse,”Neuromuscular Disorders12:S90-S94 (2002).
Grady et al., “Skeletal and Cardiac Myopathies in Mice Lacking Utrophin and Dystrophin: A Model for Duchenne Muscular Dystrophy,”Cell90:729-738 (1997).
Gonzalez-Cadavid et al., “Organization of the Human Myostatin Gene and Expression in Healthy Men and HIV-Infected Men With Muscle Wasting”,PNAS95:14938-14943 (1998).
Granchelli et al., “Pre-Clinical Screening of Drugs Using themdxMouse,”Neuromuscular Disorders10:235-239 (2000).
Hamrick et al., “Bone Mineral Content and Density in the Humerus of Adult Myostatin-Deficient Mice,”Calcif. Tissue Int. 71(1):63-68 (2002).
Hamrick et al., “Femoral Morphology and Cross-Sectional Geometry of Adult Myostatin-Deficient Mice”,Bone27:343-349 (2000).
Ha

Affiliated with

Also associated with

Rating

Neutralizing antibodies against GDF-8 and uses therefor does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Neutralizing antibodies against GDF-8 and uses therefor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Neutralizing antibodies against GDF-8 and uses therefor will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4161447